Formation of large protein fibrils with a characteristic cross -sheet architecture is the key molecular event underlying a wide variety of systemic and neurodegenerative amyloid diseases [1]. Elucidating the mechanisms that regulate amyloid fibril self-assembly is one approach towards developing new drugs and treatment strategies. Recent experiments have strongly implicated oligomeric intermediates, transiently formed during fibril assembly, as critical contributors to cellular toxicity in amyloid diseases. Yet, amyloid fibril assembly can apparently proceed along different assembly pathways that might or might not involve such oligomeric intermediates. Elucidating the mechanisms that determine whether fibril formation involves nonoligomeric or oligomeric pathways, therefore, could have direct implications for development of novel drugs trying to switch assembly from toxic to non-toxic pathways.
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